Following the European Commission’s implementing decision (EU) 2018/2013 of 14 December 2018, 1,7,7-trimethyl-3-(phenylmethylene)bicyclo[2.2.1]heptan-2-one(3-benzylidene camphor) was identified and added to the list of substances of very high concern (SVHC list).
This substance had already been presented to the Agency’s Member State Committee by Germany in February 2016. A file had been prepared in accordance with Annex XV to demonstrate the negative impact of this substance on the endocrine system and the environment. The Member State Committee previously had not been able to rule on the dangerousness of 3-benzylidene camphor as several members have expressed doubts about the associated scientific analysis.
In June 2016, the CEM’s opinion was forwarded to the Commission for a decision on the status of 3-benzylidene camphor. Based on the data in the Annex XV dossier, the Commission and the members of the CEM have ruled that this substance alters the functioning of the endocrine system of wild animals and in particular has irreversible effects on fish fertility. 3-Benzylidene camphor was therefore subsequently recognized as an endocrine disruptor according to the WHO definition and added to the SVHC list on 18 December 2018. Users of this substance are now required to inform their customers of its presence in their product if its concentration is equal to or greater than 0.1% (Article 33 of REACh).
This same substance was already banned in cosmetic products distributed in France in 2011 following a decision by the Afssaps before being published in the official journal on 19 September 2011. The European Commission then prohibited it by amending Regulation 2015/1298 of 28 July 2015.
Source: DECISION
IMPLEMENTATION (EU) 2018/2013 OF THE COMMISSION of 14 December 2018
